 










MPM Capital appoints Pablo J. Cagnoni, M.D., former Onyx Pharmaceuticals President, as Managing Director and CEO of MPM immunotherapy portfolio company Vesuvius - MPM Capital




























































 Back to press


May 21, 2015



SAN FRANCISCO–(BUSINESS WIRE)–MPM Capital announces the appointment of former President of Onyx Pharmaceuticals Pablo J. Cagnoni, M.D. as Managing Director (MD). In addition to serving as an MPM MD, Dr. Cagnoni is a co-founder of Vesuvius, an MPM-founded cancer immunotherapy company, and has taken on the role of President and Chief Executive Officer.
“Pablo brings tremendous operating and clinical development expertise to MPM Capital and its portfolio of investee companies developing breakthrough products”
Over of the course of his career as an oncologist and pharmaceutical executive, Dr. Cagnoni has been committed to advancing the development of breakthrough treatments for patients with cancer and other debilitating diseases. He has played a key role in the development, approval and/or commercialization of several life-changing medicines, including Afinitor®, Blinctyo®, Exjade®, Folotyn®, Glivec®, Jakavi®, Kyprolis®, Signifor®, Tarceva® and Tasigna®, among them.
“Pablo brings tremendous operating and clinical development expertise to MPM Capital and its portfolio of investee companies developing breakthrough products,” said Luke Evnin, MPM Capital Managing Director and co-founder. “We feel honored and gratified that Pablo chose MPM and our portfolio company Vesuvius as the best platform for him to continue his significant contributions to the development of innovative oncology medicines.”
“MPM’s world-class team has already demonstrated great success in the area of immuno-oncology with investments such as CoStim. I am confident that Vesuvius, with its distinguished scientific advisory board and scientifically-renowned co-founders, is poised to develop equally innovative breakthrough therapies,” said Dr. Cagnoni.
As President of Onyx Pharmaceuticals Dr. Cagnoni had global strategic oversight and accountability of the business from early product development to commercialization. At the time of his departure, Onyx was on track to deliver yearly revenues in excess of $1B and had over 800 employees. Dr. Cagnoni joined Onyx in March 2013 as Executive Vice President, Global Research and Development and Technical Operations, and was named President in October 2013, when Onyx became an Amgen subsidiary. Previously, he was Senior Vice President and Global Head of Clinical Development at Novartis Oncology, where he was responsible for all clinical development, clinical operations, clinical pharmacology and correlative sciences activities for the oncology development pipeline. From 2007 to 2009, Dr. Cagnoni was Senior Vice President and Chief Medical Officer at Allos Therapeutics, and prior to that Chief Medical Officer of OSI Pharmaceuticals. Earlier in his career, he served as Assistant Professor of Medicine, University of Colorado Bone Marrow Transplant Program where he cared for patients undergoing stem cell transplant.
Dr. Cagnoni earned his medical degree from University of Buenos Aires School of Medicine, and he completed his fellowship in Hematology and Oncology in Mount Sinai Medical Center, New York and a fellowship in Stem Cell Transplantation at the University of Colorado Health Sciences Center
About MPM Capital — MPM Capital (http://www.mpmcapital.com) is a global leader in early-stage life sciences venture investing with a track record of success in building world-class companies around transformational treatments and cures. With its deep experience, dedicated team of operating executives and distinguished MSAB, MPM Capital is powering medical breakthroughs that change lives.
Contacts
FOR FURTHER INFORMATION:
MPM Capital
Sarah Reed, 1-617-425-9205
sreed@mpmcapital.com












X










X










X

































Pablo J. Cagnoni M.D.: Executive Profile & Biography - Bloomberg









































  





















































































July 21, 2017 2:45 PM ET
Biotechnology

Company Overview of Tizona Therapeutics, Inc.



SnapshotPeople 




OverviewBoard MembersCommittees



Executive Profile
Pablo J. Cagnoni M.D.Co-Founder, Chief Executive Officer, President and Director, Tizona Therapeutics, Inc.AgeTotal Calculated CompensationThis person is connected to 3 Board Members in 3 different organizations across 5 different industries.See Board Relationships54--
Background

		Dr. Pablo J. Cagnoni, M.D., is Co-Founder, Chief Executive Officer and President of Tizona Therapeutics, Inc. He is the Executive Chairman of Blade Therapeutics. He served as a Managing Director at MPM Capital since May 20, 2015. He served as the President of Onyx Pharmaceuticals, Inc. since October 2013, where he had global strategic oversight and accountability of the business from early product development to commercialization of the Onyx portfolio. Dr. Cagnoni joined ... Onyx in March 2013. He served as an Executive Vice President of Global Research & Development and Technical Operations at Onyx Pharmaceuticals, Inc. since March 2013. At Onyx, he had global strategic oversight and accountability of the business from early product development to commercialization. Previously, he was Senior Vice President and Global Head of Clinical Development at Novartis Oncology, where he was responsible for all clinical development, clinical operations, clinical pharmacology and correlative sciences activities for the oncology development pipeline. He served as the Chief Medical Officer and Senior Vice President of Allos Therapeutics, Inc. from March 20, 2007 to September 30, 2009. He led Allos Therapeutics Inc.'s clinical development functions, including clinical operations, medical affairs and biometrics. From 2004 to 2007, he held several key management positions with OSI Pharmaceuticals, Inc., served as the Chief Medical Officer and Vice President of Clinical Research and Medical Affairs since December 18, 2006. He oversaw all of the clinical development and medical affairs activities of OSI Pharmaceuticals's oncology portfolio which includes further development of its flagship product Tarceva. He has almost 20 years of clinical development experience in oncology in both the biotechnology and the academic settings. He served as Vice President of Medical Affairs, Clinical Development and Translational Research of Osi Pharmaceuticals Inc. and served as an Interim Senior Medical Officer For Oncology Clinical Development since May 1, 2005. He served as Allos Therapeutics, Inc.'s Consultant for clinical development and regulatory activities since August 2004. He served at Allos Therapeutics Inc., as Vice President of Clinical Development from March 2003 to August 2004 and served as Senior Medical Director from June 2002 to February 2003 and as a Director of Clinical Development from July 2001 to June 2002. Prior to Allos Therapeutics Inc., he served as an Assistant Professor of Medicine in the Division of Oncology at the University of Colorado, where he also served as an Assistant Director of the Pharmacology Laboratory and Member of the Bone Marrow Transplant Program and a Member of the University of Colorado Cancer Center. He has been a Director of Lycera Corp. since March 13, 2017. Dr. Cagnoni serves as a Director of Harpoon Therapeutics. He has been an Independent Director of CRISPR Therapeutics AG since December 2015. He also serves as a Director of Tizona Therapeutics, Inc. He has authored over 50 publications, numerous book chapters and has lectured extensively in several areas related to clinical oncology and drug development. He has 25-year career as an oncologist and biopharmaceutical innovator.Over of the course of his career, Dr. Cagnoni has played a key role in the development, approval and/or commercialization of several life-changing medicines, including Afinitor®, Blincyto® Exjade®, Folotyn® Glivec®, Jakavi®, Kyprolis®, Signifor®, Tarceva®, Tasigna® and Zykadia® among them. Dr. Cagnoni earned his M.D. from the University Buenos Aires School of Medicine and he completed his fellowship in Hematology and Oncology at The Mount Sinai Medical Center, New York and in Bone Marrow Transplantation at the University of Colorado. Dr. Cagnoni completed a fellowship in Stem Cell Transplantation at the University of Colorado Health Sciences Center. He graduated Summa Cum Laude from the University of Buenos Aires Medical School.Read Full Background




Corporate Headquarters
601 Gateway BoulevardSouth San Francisco, California 94080United StatesPhone: --Fax: --
Board Members Memberships
Co-Founder, Chief Executive Officer, President and DirectorTizona Therapeutics, Inc.2015-PresentIndependent DirectorCRISPR Therapeutics AG2017-PresentDirectorLycera Corp.
Education
MD Universidad de Buenos Aires
Other Affiliations
MPM CapitalAllos Therapeutics, Inc.Onyx Pharmaceuticals, Inc.OSI Pharmaceuticals Inc.Universidad de Buenos AiresLycera Corp.CRISPR Therapeutics AG


Annual Compensation
				There is no Annual Compensation data available.
				Stocks Options
				There is no Stock Options data available.
				Total Compensation
				There is no Total Compensation data available.
			



Request Profile Update
















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



COMPETITOR COMPENSATIONThere is no Competitor Compensation data available.










Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact Tizona Therapeutics, Inc., please visit .  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close


























 



MPM Capital appoints Pablo J. Cagnoni, M.D., former Onyx Pharmaceuticals President, as Managing Director and CEO of MPM immunotherapy portfolio company Vesuvius. | Business Wire
























































MPM Capital appoints Pablo J. Cagnoni, M.D., former Onyx 
      Pharmaceuticals President, as Managing Director and CEO of MPM 
      immunotherapy portfolio company Vesuvius.






May 20, 2015 10:13 AM Eastern Daylight Time



SAN FRANCISCO--(BUSINESS WIRE)--MPM 
      Capital announces the appointment of former President of Onyx 
      Pharmaceuticals Pablo J. Cagnoni, M.D. as Managing Director (MD). In 
      addition to serving as an MPM MD, Dr. Cagnoni is a co-founder of 
      Vesuvius, an MPM-founded cancer immunotherapy company, and has taken on 
      the role of President and Chief Executive Officer.
    


      Over of the course of his career as an oncologist and pharmaceutical 
      executive, Dr. Cagnoni has been committed to advancing the development 
      of breakthrough treatments for patients with cancer and other 
      debilitating diseases. He has played a key role in the development, 
      approval and/or commercialization of several life-changing medicines, 
      including Afinitor®, Blinctyo®, Exjade®, Folotyn®, Glivec®, Jakavi®, 
      Kyprolis®, Signifor®, Tarceva® and Tasigna®, among them.
    

      “Pablo brings tremendous operating and clinical development expertise to 
      MPM Capital and its portfolio of investee companies developing 
      breakthrough products,” said Luke Evnin, MPM Capital Managing Director 
      and co-founder. “We feel honored and gratified that Pablo chose MPM and 
      our portfolio company Vesuvius as the best platform for him to continue 
      his significant contributions to the development of innovative oncology 
      medicines.”
    

      “MPM’s world-class team has already demonstrated great success in the 
      area of immuno-oncology with investments such as CoStim. I am confident 
      that Vesuvius, with its distinguished scientific advisory board and 
      scientifically-renowned co-founders, is poised to develop equally 
      innovative breakthrough therapies,” said Dr. Cagnoni.
    

      As President of Onyx Pharmaceuticals Dr. Cagnoni had global strategic 
      oversight and accountability of the business from early product 
      development to commercialization. At the time of his departure, Onyx was 
      on track to deliver yearly revenues in excess of $1B and had over 800 
      employees. Dr. Cagnoni joined Onyx in March 2013 as Executive Vice 
      President, Global Research and Development and Technical Operations, and 
      was named President in October 2013, when Onyx became an Amgen 
      subsidiary. Previously, he was Senior Vice President and Global Head of 
      Clinical Development at Novartis Oncology, where he was responsible for 
      all clinical development, clinical operations, clinical pharmacology and 
      correlative sciences activities for the oncology development pipeline. 
      From 2007 to 2009, Dr. Cagnoni was Senior Vice President and Chief 
      Medical Officer at Allos Therapeutics, and prior to that Chief Medical 
      Officer of OSI Pharmaceuticals. Earlier in his career, he served as 
      Assistant Professor of Medicine, University of Colorado Bone Marrow 
      Transplant Program where he cared for patients undergoing stem cell 
      transplant.
    

      Dr. Cagnoni earned his medical degree from University of Buenos Aires 
      School of Medicine, and he completed his fellowship in Hematology and 
      Oncology in Mount Sinai Medical Center, New York and a fellowship in 
      Stem Cell Transplantation at the University of Colorado Health Sciences 
      Center
    

      About MPM Capital -- MPM Capital (http://www.mpmcapital.com) 
      is a global leader in early-stage life sciences venture investing with a 
      track record of success in building world-class companies around 
      transformational treatments and cures. With its deep experience, 
      dedicated team of operating executives and distinguished MSAB, MPM 
      Capital is powering medical breakthroughs that change lives.
    




Contacts

      FOR FURTHER INFORMATION:MPM CapitalSarah Reed, 1-617-425-9205sreed@mpmcapital.com
















Contacts

      FOR FURTHER INFORMATION:MPM CapitalSarah Reed, 1-617-425-9205sreed@mpmcapital.com







 
 

 






Search




Advanced News Search

Advanced News Search













Log In
Sign Up












 



CRISPR Therapeutics Adds Pablo J. Cagnoni, M.D., to Board of Directors and Names Tony Coles, M.D., Chairman of the Board to Enhance Drug Development and Commercialization Expertise | Business Wire


























































CRISPR Therapeutics Adds Pablo J. Cagnoni, M.D., to Board of 
      Directors and Names Tony Coles, M.D., Chairman of the Board to Enhance 
      Drug Development and Commercialization Expertise












Download



Full Size


Small


Preview


Thumbnail










CRISPR Therapeutics Adds Pablo J. Cagnoni, M.D., to Board of Directors (Photo: Business Wire)


???pagination.previous???
???pagination.next???







CRISPR Therapeutics Adds Pablo J. Cagnoni, M.D., to Board of Directors (Photo: Business Wire)





Full Size








Small








Preview








Thumbnail












CRISPR Therapeutics Names Tony Coles, M.D., Chairman of the Board (Photo: Business Wire)





Full Size








Small








Preview








Thumbnail


















Full Size








Small








Preview








Thumbnail














March 17, 2016 07:00 AM Eastern Daylight Time



BASEL, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--CRISPR 
      Therapeutics, a biopharmaceutical company focused on developing 
      transformative gene-based medicines for patients with serious diseases, 
      today announced the appointment of Pablo J. Cagnoni, M.D., to its board 
      of directors. The Company also named current board member, Tony Coles, 
      M.D., as new Chairman of the Board. Dr. Coles succeeds Bradley Bolzon, 
      M.D., Managing Director of Versant Ventures and Founding Chairman since 
      2013.
    


      “As Pablo and Tony transition into their new roles, I would like to 
      thank Brad for his leadership and commitment as our Chairman since 
      inception, and am very pleased he will continue guiding the Company as a 
      director,” said Rodger Novak, M.D., Chief Executive Officer of CRISPR 
      Therapeutics. “Pablo is an ideal addition with his deep experience in 
      drug development, translating breakthrough therapeutic approaches into 
      highly innovative drugs for people with cancer and other debilitating 
      diseases. His experience partnering with the medical community to 
      transform treatment paradigms will help expedite the development of 
      novel therapeutics derived from our proprietary technology platform.”
    

      During Dr. Cagnoni’s 25-year career as an oncologist and 
      biopharmaceutical innovator, he has played a key role in the 
      development, approval and/or commercialization of several life-changing 
      medicines, most notably Tarceva®, Afinitor®, and 
      Kyprolis®. Dr. Cagnoni, who has served as Managing Director 
      of MPM Capital since 2015, is currently President and Chief Executive 
      Officer of Tizona Therapeutics and Executive Chairman of Blade 
      Therapeutics. Before this, Dr. Cagnoni served as President of Onyx 
      Pharmaceuticals, a subsidiary of Amgen, where he had global strategic 
      oversight and accountability of the business from early product 
      development to commercialization of the Onyx portfolio.
    

      “I am honored and excited to join CRISPR Therapeutics’ Board at a time 
      when its technology has the potential to revolutionize the treatment of 
      some of the world’s most intractable diseases,” said Dr. Cagnoni. 
      “CRISPR Therapeutics has the technology, scientific rigor, resources, 
      world-class team and partners necessary to realize its ambitious 
      mission.”
    

      CRISPR Therapeutics is focused on the discovery and development of 
      potential cures for serious diseases using its proprietary CRISPR-Cas9 
      gene editing technology. The Company’s multi-disciplinary team of 
      world-class drug developers, clinicians and academics is working on its 
      own proprietary product pipeline and also partnering with some of the 
      world’s leading pharmaceutical and biotechnology companies to translate 
      this technology into breakthrough human therapeutics. The foundational 
      CRISPR-Cas9 patent estate for human therapeutic use was licensed from 
      scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics 
      recently entered into substantial strategic partnerships with Vertex 
      Pharmaceuticals and Bayer.
    

      Prior to his tenure at Onyx/Amgen, Dr. Cagnoni served in executive 
      global development roles at Novartis Oncology, Allos Therapeutics 
      (acquired by Spectrum Pharmaceuticals) and OSI Pharmaceuticals (acquired 
      by Astellas). Dr. Cagnoni earned his medical degree from the University 
      of Buenos Aires School of Medicine, and completed his fellowships in 
      Hematology and Oncology at Mount Sinai Medical Center in New York and in 
      stem cell transplantation at the University of Colorado Health Sciences 
      Center. Before joining industry, he served as Assistant Professor of 
      Medicine at the University of Colorado Bone Marrow Transplant Program.
    

      Dr. Coles joined the Board of Directors of CRISPR Therapeutics in December 
      2015, and currently serves as Chairman and Chief Executive Officer 
      of Yumanity Therapeutics, a biotechnology company focused on 
      transforming drug discovery for neurodegenerative diseases caused by 
      protein misfolding. Prior to founding Yumanity, Dr. Coles was Chairman 
      and Chief Executive Officer of Onyx Pharmaceuticals. Previously, he held 
      various executive and leadership positions at NPS Pharmaceuticals, 
      Vertex Pharmaceuticals, Bristol-Myers Squibb Company and Merck & Co.
    

      CRISPR Therapeutics is headquartered in Basel, Switzerland with its R&D 
      operations based in Cambridge, Massachusetts. For more information, 
      please visit www.crisprtx.com.
    




Contacts

W2O Group for CRISPRJennifer Paganelli, 347-658-8290jpaganelli@w2ogroup.com
















Release Summary
CRISPR Therapeutics Adds Pablo J. Cagnoni, M.D., to Board of Directors and Names Tony Coles, M.D., Chairman of the Board to Enhance Drug Development and Commercialization Expertise





Social Media Profiles

CRISPR Therapeutics
CRISPR Therapeutics





Contacts

W2O Group for CRISPRJennifer Paganelli, 347-658-8290jpaganelli@w2ogroup.com









 
 

 






Search




Advanced News Search

Advanced News Search













Log In
Sign Up

































 



 Lycera Announces the Appointment of Pablo J. Cagnoni, M.D., to the Board of Directors 
         










    










 













 











 



















Lycera Announces the Appointment of Pablo J. Cagnoni, M.D., to the Board of Directors
        																																												
              
















 News provided by
Lycera Corp.  
Mar 13, 2017, 08:00 ET









 Share this article




























































NEW YORK and ANN ARBOR, Mich., March 13, 2017 /PRNewswire/ -- Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today that Pablo J. Cagnoni, M.D., has been elected to the Company's Board of Directors, effective immediately. The Company also announced that Timothy M. Mayleben will step down from his position on Lycera's Board.








"Pablo brings to our Board an acclaimed track record in drug R&D, having played a key role in the development and commercialization of several life-changing medicines for people with cancer and other debilitating diseases," said Paul Sekhri, President and CEO of Lycera. "We believe both his experience as a clinician and his deep operational expertise will have a profound impact as we continue to advance our pipeline of innovative clinical-stage candidates. Pablo's breadth of clinical development experience and his comprehensive understanding of the regulatory process are just two reasons why I am thrilled to have him join our Board at this pivotal and exciting time for Lycera."
Mr. Sekhri added, "As we welcome Pablo to the Board, we would also like to offer our sincere gratitude to Tim Mayleben for his years of dedicated service. Tim's contributions have been important to Lycera in advancing our two novel programs in the clinic, entering into a strategic alliance with Celgene, and creating a world-class team focused on discovering and developing new therapies in autoimmune disease and immuno-oncology."
Dr. Cagnoni, throughout his 25-year career as an oncologist and biopharmaceutical executive, has played a key role in the development, approval, and/or commercialization of several life-changing medicines including Afinitor®, Blincyto®, Exjade®, Folotyn®, Glivec®, Jakavi®, Kyprolis®, Signifor®, Tarceva®, Tasigna®, and Zykadia®. Dr. Cagnoni is President and Chief Executive Officer of Tizona Therapeutics, an immunology company that is harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Prior to this role, he served as President of Onyx Pharmaceuticals, a subsidiary of Amgen, where he was directly responsible for the Onyx portfolio from early product development through commercialization. Previously, Dr. Cagnoni served in executive global development roles at Novartis Oncology, Allos Therapeutics (acquired by Spectrum Pharmaceuticals), and OSI Pharmaceuticals (acquired by Astellas). He is also a Director of CRISPR Therapeutics and Harpoon Therapeutics. Dr. Cagnoni earned his medical degree from the University of Buenos Aires School of Medicine, and completed his fellowships in Hematology and Oncology at Mount Sinai Medical Center in New York and in stem cell transplantation at the University of Colorado Health Sciences Center. Before joining the biopharma industry, he served as Assistant Professor of Medicine at the University of Colorado Bone Marrow Transplant Program.
"Lycera has built a world-class R&D engine with an innovative, clinical-stage pipeline that is addressing some of the most pressing needs in cancer and autoimmune diseases today," said Dr. Cagnoni. "Joining the Board of Directors and working alongside the impressive team at Lycera is an incredible opportunity to help accelerate the Company's broad pipeline."
About Lycera
Lycera is a biopharmaceutical company developing novel oral immune modulators for the treatment of autoimmune diseases and cancer. Based on successful progress of its world-class R&D platform, including expertise in immune metabolism, cell signaling, and immune cell differentiation, Lycera commenced multiple clinical programs in 2016. The company is advancing a wholly owned, oral, gut-directed ATPase modulator, designated LYC-30937-EC, for the treatment of autoimmune disease, and has entered Phase 2 clinical studies in patients with ulcerative colitis and psoriasis. A second product candidate, LYC-55716, an oral RORgamma agonist, has progressed into Phase 1/2a testing in patients with advanced solid tumors. Lycera has an exclusive strategic collaboration with Celgene Corporation to advance Lycera's proprietary pipeline for cancer and immune-mediated diseases. In addition, Lycera had previously established collaborations with Merck to discover, develop, and commercialize small molecule therapies for autoimmune disorders.
Lycera's leadership possesses deep experience in drug discovery, development, and commercialization and has established close relationships with renowned thought leaders and clinical researchers worldwide. Lycera was founded in 2006 based on an initial scientific platform in-licensed from the University of Michigan. Lead investors in Lycera include InterWest Partners, ARCH Venture Partners, Clarus Ventures, and EDF Ventures.
CONTACT: Justin Jackson, Burns McClellan, 212-213-0006, ext. 327, jjackson@burnsmc.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lycera-announces-the-appointment-of-pablo-j-cagnoni-md-to-the-board-of-directors-300422344.html
SOURCE Lycera Corp.
 Related Links

http://www.lycera.com



 













Jan 04, 2017, 08:00 ET
Preview: Lycera Announces Initiation of Phase 1/2a Study ARGON of Immuno-Oncology Candidate LYC-55716 in Patients with Advanced Solid Tumors






My News


  Release contains wide tables.	  View fullscreen.





 You just read:
Lycera Announces the Appointment of Pablo J. Cagnoni, M.D., to the Board of Directors


 News provided by
Lycera Corp.  
Mar 13, 2017, 08:00 ET








 Share this article









































 











Looking to send a news release with PR Newswire?
Take advantage of the world's leading distribution platform.
Sign up to get started
Request more information
Have an account? Log In

















Search











Searching for your content...









Advanced Search












































 


   Pablo Cagnoni | Tizona Therapeutics Inc | ZoomInfo.com




Lycera Announces the Appointment of Pablo J. Cagnoni, M.D. to the Board of Directors – Lycera































































Lycera Announces the Appointment of Pablo J. Cagnoni, M.D. to the Board of Directors














  Mar 13, 2017





NEW YORK and ANN ARBOR, Mich., Mar. 13, 2017 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today that Pablo J. Cagnoni, M.D., has been elected to the Company’s Board of Directors, effective immediately. The Company also announced that Timothy M. Mayleben will step down from his position on Lycera’s Board.
“Pablo brings to our Board an acclaimed track record in drug R&D, having played a key role in the development and commercialization of several life-changing medicines for people with cancer and other debilitating diseases,” said Paul Sekhri, President and CEO of Lycera. “We believe both his experience as a clinician and his deep operational expertise will have a profound impact as we continue to advance our pipeline of innovative clinical-stage candidates. Pablo’s breadth of clinical development experience and his comprehensive understanding of the regulatory process are just two reasons why I am thrilled to have him join our Board at this pivotal and exciting time for Lycera.”
Mr. Sekhri added, “As we welcome Pablo to the Board, we would also like to offer our sincere gratitude to Tim Mayleben for his years of dedicated service. Tim’s contributions have been important to Lycera in advancing our two novel programs in the clinic, entering into a strategic alliance with Celgene, and creating a world-class team focused on discovering and developing new therapies in autoimmune disease and immuno-oncology.”
Dr. Cagnoni, throughout his 25-year career as an oncologist and biopharmaceutical executive, has played a key role in the development, approval, and/or commercialization of several life-changing medicines including Afinitor®, Blincyto®, Exjade®, Folotyn®, Glivec®, Jakavi®, Kyprolis®, Signifor®, Tarceva®, Tasigna®, and Zykadia®. Dr. Cagnoni is President and Chief Executive Officer of Tizona Therapeutics, an immunology company that is harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Prior to this role, he served as President of Onyx Pharmaceuticals, a subsidiary of Amgen, where he was directly responsible for the Onyx portfolio from early product development through commercialization. Previously, Dr. Cagnoni served in executive global development roles at Novartis Oncology, Allos Therapeutics (acquired by Spectrum Pharmaceuticals), and OSI Pharmaceuticals (acquired by Astellas). He is also a Director of CRISPR Therapeutics and Harpoon Therapeutics. Dr. Cagnoni earned his medical degree from the University of Buenos Aires School of Medicine, and completed his fellowships in Hematology and Oncology at Mount Sinai Medical Center in New York and in stem cell transplantation at the University of Colorado Health Sciences Center. Before joining the biopharma industry, he served as Assistant Professor of Medicine at the University of Colorado Bone Marrow Transplant Program.
“Lycera has built a world-class R&D engine with an innovative, clinical-stage pipeline that is addressing some of the most pressing needs in cancer and autoimmune diseases today,” said Dr. Cagnoni. “Joining the Board of Directors and working alongside the impressive team at Lycera is an incredible opportunity to help accelerate the Company’s broad pipeline.”
About Lycera
Lycera is a biopharmaceutical company developing novel oral immune modulators for the treatment of autoimmune diseases and cancer. Based on successful progress of its world-class R&D platform, including expertise in immune metabolism, cell signaling, and immune cell differentiation, Lycera commenced multiple clinical programs in 2016. The company is advancing a wholly owned, oral, gut-directed ATPase modulator, designated LYC-30937-EC, for the treatment of autoimmune disease, and has entered Phase 2 clinical studies in patients with ulcerative colitis and psoriasis. A second product candidate, LYC-55716, an oral RORgamma agonist, has progressed into Phase 1/2a testing in patients with advanced solid tumors. Lycera has an exclusive strategic collaboration with Celgene Corporation to advance Lycera’s proprietary pipeline for cancer and immune-mediated diseases. In addition, Lycera had previously established collaborations with Merck to discover, develop, and commercialize small molecule therapies for autoimmune disorders.
Lycera’s leadership possesses deep experience in drug discovery, development, and commercialization and has established close relationships with renowned thought leaders and clinical researchers worldwide. Lycera was founded in 2006 based on an initial scientific platform in-licensed from the University of Michigan. Lead investors in Lycera include InterWest Partners, ARCH Venture Partners, Clarus Ventures, and EDF Ventures.
CONTACT: Justin Jackson, Burns McClellan, 212-213-0006, ext. 327, jjackson@burnsmc.com
 























	MPM Capital appoints Pablo J. Cagnoni, M.D., former Onyx Pharmaceuticals President, as Managing Director and CEO of MPM immunotherapy portfolio company Vesuvius.































MENU 

MENU

Home
Optical Networking 
Virtualization
Hyperscale Data Centers
eNews 
 Contact Us 
 RSS Feeds 














     
   Transforming Network Infrastructure Industry News 




 




















[May 20, 2015]


MPM Capital appoints Pablo J. Cagnoni, M.D., former Onyx Pharmaceuticals President, as Managing Director and CEO of MPM immunotherapy portfolio company Vesuvius.


MPM 
 Capital announces the appointment of former President of Onyx 
 Pharmaceuticals Pablo J. Cagnoni, M.D. as Managing Director (MD). In 
 addition to serving as an MPM MD, Dr. Cagnoni is a co-founder of 
 Vesuvius, an MPM-founded cancer immunotherapy company, and has taken on 
 the role of President and Chief Executive Officer.
 

 Over of the course of his career as an oncologist and pharmaceutical 
 executive, Dr. Cagnoni has been committed to advancing the development 
 of breakthrough treatments for patients with cancer and other 
 debilitating diseases. He has played a key role in the development, 
 approval and/or commercialization of several life-changing medicines, 
 including Afinitor®, Blinctyo®, Exjade®, Folotyn®, Glivec®, Jakavi®, 
 Kyprolis®, Signifor®, Tarceva® and Tasigna®, among them.
 

 "Pablo brings tremendous operating and clinical development expertise to 
 MPM Capital and its portfolio of investee companies developing 
 breakthrough products," said Luke Evnin, MPM Capital Managing Director 
 and co-founder. "We feel honored and gratified that Pablo chose MPM and 
 our portfolio company Vesuvius as the best platform for him to continue 
 his significant cotributions to the development of innovative oncology 
 medicines."
 
 

 "MPM's world-class team has already demonstrated great success in the 
 area of immuno-oncology with investments such as CoStim. I am confident 
 that Vesuvius, with its distinguished scientific advisory board and 
 scientifically-renowned co-founders, is poised to develop equally 
 innovative breakthrough therapies," said Dr. Cagnoni.
 

 As President of Onyx Pharmaceuticals Dr. Cagnoni had global strategic 
 oversight and accountability of the business from early product 
 development to commercialization. At the time of his departure, Onyx was 
 on track to deliver yearly revenues in excess of $1B and had over 800 
 employees. Dr. Cagnoni joined Onyx in March 2013 as Executive Vice 
 President, Global Research and Development and Technical Operations, and 
 was named President in October 2013, when Onyx became an Amgen 
 subsidiary. Previously, he was Senior Vice President and Global Head of 
 Clinical Development at Novartis Oncology, where he was responsible for 
 all clinical development, clinical operations, clinical pharmacology and 
 correlative sciences activities for the oncology development pipeline. 
 From 2007 to 2009, Dr. Cagnoni was Senior Vice President and Chief 
 Medical Officer at Allos Therapeutics, and prior to that Chief Medical 
 Officer of OSI Pharmaceuticals. Earlier in his career, he served as 
 Assistant Professor of Medicine, University of Colorado Bone Marrow 
 Transplant Program where he cared for patients undergoing stem cell 
 transplant.
 

 Dr. Cagnoni earned his medical degree from University of Buenos Aires 
 School of Medicine, and he completed his fellowship in Hematology and 
 Oncology in Mount Sinai Medical Center, New York and a fellowship in 
 Stem Cell Transplantation at the University of Colorado Health Sciences 
 Center
 

 About MPM Capital -- MPM Capital (http://www.mpmcapital.com) 
 is a global leader in early-stage life sciences venture investing with a 
 track record of success in building world-class companies around 
 transformational treatments and cures. With its deep experience, 
 dedicated team of operating executives and distinguished MSAB, MPM 
 Capital is powering medical breakthroughs that change lives.
 


View source version on businesswire.com: http://www.businesswire.com/news/home/20150520005926/en/

[ Back To Transforming Network Infrastructure's Homepage ]






 
Home
 
















Click here to share your opinion - Has your company evaluated how to integrate AI, Artificial Intelligence, into your operations workstreams?








 
  
Featured Blog Entries 








Day 3 at Interop ITX 2017, the final day!!
We had an eventful week exhibiting at Interop ITX! After lots of great conversations, a well-attended presentation by our CEO M.H. Raza about "Automating the Physical Layer," and a wealth of different answers to our survey questions, it's time to travel home to Connecticut. First, though, here's a roundup of day 3!








Day 2 at Interop ITX 2017, top of the stretch!
The middle and longest day was filled with:

Fiber Mountain sponsored an Interop ITX Theater presentation on Wednesday 5/17 delivered by M.H. Raza, Fiber Mountain CEO, entitled, "Automating the Physical Layer". The audience was standing room only and several attendees came to our booth immediately after the presentation and learned more about the Glass Core.








...and We're off, at Interop ITX 2017!
 
We are back in Las Vegas, this time at Interop ITX 2017, the rejuvenated version of Interop. As I have written in the past, Interop has a long history back to the mid-1980's and has reinvented itself many times. Interop ITX 2017 is the newest edition, with only paid attendees and no more free passes to the expo floor. UBM, the owner of Interop, intends to increase the quality of attendees, sessions and leads for exhibitors and sponsors.






Industry News  








  Webinar Announced: How to Know if Your Cloud Decision is Right for Your SMB
07/21/2017
  Global $7.8 Billion Hyperscale Data Center Market Analysis & Trends 2014-2025
07/21/2017
  The C-RAN (Centralized Radio Access Network) Ecosystem: 2017 - 2030 - Opportunities, Challenges, Strategies & Forecasts
07/20/2017
  Global IT-as-a-Service Market - Analysis,Technologies & Forecasts to 2021 - Key Players are BMC Software, HPE, IBM, Red Hat & VMware
07/20/2017






 




























Request unsuccessful. Incapsula incident ID: 574000390030971813-19667157797175922